These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 9353388)

  • 1. Human CYP2C9 and CYP2A6 mediate formation of the hepatotoxin 4-ene-valproic acid.
    Sadeque AJ; Fisher MB; Korzekwa KR; Gonzalez FJ; Rettie AE
    J Pharmacol Exp Ther; 1997 Nov; 283(2):698-703. PubMed ID: 9353388
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Contribution of CYP2C9, CYP2A6, and CYP2B6 to valproic acid metabolism in hepatic microsomes from individuals with the CYP2C9*1/*1 genotype.
    Kiang TK; Ho PC; Anari MR; Tong V; Abbott FS; Chang TK
    Toxicol Sci; 2006 Dec; 94(2):261-71. PubMed ID: 16945988
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of Ginkgo biloba extract on oxidative metabolism of valproic acid in hepatic microsomes from donors with the CYP2C9*1/*1 genotype.
    Numa AM; Abbott FS; Chang TK
    Can J Physiol Pharmacol; 2007 Sep; 85(9):848-55. PubMed ID: 18066130
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations of CYP2C9 and CYP2A6 Polymorphisms with the Concentrations of Valproate and its Hepatotoxin Metabolites and Valproate-Induced Hepatotoxicity.
    Zhao M; Zhang T; Li G; Qiu F; Sun Y; Zhao L
    Basic Clin Pharmacol Toxicol; 2017 Aug; 121(2):138-143. PubMed ID: 28273397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Influence of CYP2C9 polymorphism on metabolism of valproate and its hepatotoxin metabolite in Iranian patients.
    Amini-Shirazi N; Ghahremani MH; Ahmadkhaniha R; Mandegary A; Dadgar A; Abdollahi M; Shadnia S; Pakdaman H; Kebriaeezadeh A
    Toxicol Mech Methods; 2010 Oct; 20(8):452-7. PubMed ID: 20602621
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro.
    Ikeda K; Yoshisue K; Matsushima E; Nagayama S; Kobayashi K; Tyson CA; Chiba K; Kawaguchi Y
    Clin Cancer Res; 2000 Nov; 6(11):4409-15. PubMed ID: 11106261
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac.
    Tang W; Stearns RA; Wang RW; Chiu SH; Baillie TA
    Chem Res Toxicol; 1999 Feb; 12(2):192-9. PubMed ID: 10027798
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CYP4 isozyme specificity and the relationship between omega-hydroxylation and terminal desaturation of valproic acid.
    Rettie AE; Sheffels PR; Korzekwa KR; Gonzalez FJ; Philpot RM; Baillie TA
    Biochemistry; 1995 Jun; 34(24):7889-95. PubMed ID: 7794900
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cytochrome P450 2C9 catalyzes indomethacin O-demethylation in human liver microsomes.
    Nakajima M; Inoue T; Shimada N; Tokudome S; Yamamoto T; Kuroiwa Y
    Drug Metab Dispos; 1998 Mar; 26(3):261-6. PubMed ID: 9492390
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of polytherapy with phenytoin, carbamazepine, and stiripentol on formation of 4-ene-valproate, a hepatotoxic metabolite of valproic acid.
    Levy RH; Rettenmeier AW; Anderson GD; Wilensky AJ; Friel PN; Baillie TA; Acheampong A; Tor J; Guyot M; Loiseau P
    Clin Pharmacol Ther; 1990 Sep; 48(3):225-35. PubMed ID: 2119269
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Influence of CYP2C9 genotypes on the formation of a hepatotoxic metabolite of valproic acid in human liver microsomes.
    Ho PC; Abbott FS; Zanger UM; Chang TK
    Pharmacogenomics J; 2003; 3(6):335-42. PubMed ID: 14597963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytochrome P-450-mediated dehydrogenation of 2-n-propyl-2(E)-pentenoic acid, a pharmacologically-active metabolite of valproic acid, in rat liver microsomal preparations.
    Kassahun K; Baillie TA
    Drug Metab Dispos; 1993; 21(2):242-8. PubMed ID: 8097692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fluorinated analogues as mechanistic probes in valproic acid hepatotoxicity: hepatic microvesicular steatosis and glutathione status.
    Tang W; Borel AG; Fujimiya T; Abbott FS
    Chem Res Toxicol; 1995; 8(5):671-82. PubMed ID: 7548749
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
    Draper AJ; Madan A; Parkinson A
    Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Structural and energetic analysis to provide insight residues of CYP2C9, 2C11 and 2E1 involved in valproic acid dehydrogenation selectivity.
    Bello M; Mendieta-Wejebe JE; Correa-Basurto J
    Biochem Pharmacol; 2014 Jul; 90(2):145-58. PubMed ID: 24794636
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human reductive halothane metabolism in vitro is catalyzed by cytochrome P450 2A6 and 3A4.
    Spracklin DK; Thummel KE; Kharasch ED
    Drug Metab Dispos; 1996 Sep; 24(9):976-83. PubMed ID: 8886607
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cytotoxicity of unsaturated metabolites of valproic acid and protection by vitamins C and E in glutathione-depleted rat hepatocytes.
    Jurima-Romet M; Abbott FS; Tang W; Huang HS; Whitehouse LW
    Toxicology; 1996 Aug; 112(1):69-85. PubMed ID: 8792850
    [TBL] [Abstract][Full Text] [Related]  

  • 18. P450-catalyzed in-chain desaturation of valproic acid: isoform selectivity and mechanism of formation of Delta 3-valproic acid generated by baculovirus-expressed CYP3A1.
    Fisher MB; Thompson SJ; Ribeiro V; Lechner MC; Rettie AE
    Arch Biochem Biophys; 1998 Aug; 356(1):63-70. PubMed ID: 9681992
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of cytochrome oxidase CYP2A6, CYP2B6, and CYP2C9 polymorphisms on the plasma concentrations of valproic acid in epileptic patients.
    Tan L; Yu JT; Sun YP; Ou JR; Song JH; Yu Y
    Clin Neurol Neurosurg; 2010 May; 112(4):320-3. PubMed ID: 20089352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of CYP2C9, CYP2A6, ACSM2A, and CPT1A gene polymorphisms with adverse effects of valproic acid in Chinese patients with epilepsy.
    Wang C; Wang P; Yang LP; Pan J; Yang X; Ma HY
    Epilepsy Res; 2017 May; 132():64-69. PubMed ID: 28315807
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.